ICON plc.
ICLRPhase 3ICON plc stands as one of the world's premier clinical research organizations, partnering with pharmaceutical, biotechnology, and medical device companies to accelerate drug development and improve patient outcomes. With a global network of clinical research units across North America and Europe, the company has conducted over 894 early-phase clinical trials in the last five years, targeting more than 32,600 healthy volunteers and patients. ICON's comprehensive service portfolio spans from first-in-human studies to late-stage trials, with particular expertise in decentralized and hybrid clinical trials that prioritize patient-centric approaches. The company leverages advanced AI technologies, digital health solutions, and therapeutic expertise across cardiovascular, oncology, neurology, rare diseases, and other critical therapeutic areas.
ICLR · Stock Price
Historical price data
AI Company Overview
ICON plc stands as one of the world's premier clinical research organizations, partnering with pharmaceutical, biotechnology, and medical device companies to accelerate drug development and improve patient outcomes. With a global network of clinical research units across North America and Europe, the company has conducted over 894 early-phase clinical trials in the last five years, targeting more than 32,600 healthy volunteers and patients. ICON's comprehensive service portfolio spans from first-in-human studies to late-stage trials, with particular expertise in decentralized and hybrid clinical trials that prioritize patient-centric approaches. The company leverages advanced AI technologies, digital health solutions, and therapeutic expertise across cardiovascular, oncology, neurology, rare diseases, and other critical therapeutic areas.
Technology Platform
ICON operates an integrated digital platform combining AI-enhanced technologies, connected devices, and clinical trial tokenization to deliver patient-centric, decentralized clinical trial solutions across all phases of drug development.
Pipeline Snapshot
4747 drugs in pipeline, 13 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| Jatenzo | Hypogonadism | Approved |
| BT524 (Part I) + BT524 (Part II) | Congenital Afibrinogenemia | Phase 3 |
| Clascoterone 5% solution + Vehicle solution | Alopecia, Androgenetic | Phase 3 |
| Clascoterone 5% solution + Vehicle solution | Alopecia, Androgenetic | Phase 3 |
| Plinabulin + Pegfilgrastim | Chemotherapy-induced Neutropenia | Phase 3 |
Opportunities
Risk Factors
Competitive Landscape
ICON competes with major CROs including IQVIA, Covance, PPD (Thermo Fisher), and Syneos Health, differentiating through its AI-enhanced technologies, patient-centric decentralized trial capabilities, and strong biotech partnerships. The company's comprehensive early-phase facilities and global therapeutic expertise provide competitive advantages in specialized markets.
Company Info
Trading
Contact
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile